41

1614

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450,

Alexandria, VA/22313-1450 on 3 November 2003

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT EXAMINING GROUP 1614 Patent Application Docket No. NPB-100D5

Serial No. 09/970,558

Jeff Lloyd, Parent Artorne

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Dwayne C. Jones

Art Unit

1614

Applicant(s) :

David A Carver, Timothy Prout, Hernita Ewald, Robyn Elliott,

Paul Handreck

Serial No.

09/970,558

Filed

October 4, 2001

NOV 0 6 2003

RECEIVED

For

Injectable Composition

TECH CENTER 1600/2900

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97 AND 1.98

Sir:

Applicants wish to bring to the attention of the Examiner certain documents which have been made of record in the Opposition Proceedings concerning the Israeli patent related to the pending patent application. The Israeli patent currently is being opposed for lack of inventive step and awaiting oral arguments.

Also enclosed is a document made of record in the Appeal from the Opposition Division's Decision revoking a related European Patent.

The undersigned hereby certifies that the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

2

Applicants respectfully assert that the substantive provisions of 37 CFR §\$1.97 and 1.98 are met by the foregoing statement.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,

Patent Attorney

Registration No. 35,589

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address: 2421 NW 41st Street Suite A-1

Gainesville, FL 32606-6669

JL/srp Enclosures as stated above

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTIMENT OF COMMISSION ON Under the Paperwork-Reduction Act-of-1995, no-persons are required to respond to a collection of information unless it contains a valid OMB complete if Known

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of 1

Complete if Known			
Application Number	09/970,558		
Filing Date	October 4, 2001		
First Named Inventor	David A. Carver		
Group Art Unit	1614		
Examiner Name	Dwayne C. Jones		
Attorney Docket Number	NPB-100D5		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	R1	Opponent's Response to the Appeal dated September 12, 2003 in the EPO, along with copies of references cited therein.			
	R2	Second Affidavit of Prof. Siegfried Blechert; opinion concerning related Israeli patent in support of the opposition filed by Teva Pharmaceuticals Industries Ltd.			
	R3				
	R4	RECEIVE	D		
	R5	NOV 0 6 2003			
	R6		/00 <i>0</i>		
	R7	TECH CENTER 1600	29 0		
	R8				
	R9				
	R10				
	R11				
	R12				
,	R13				

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.